Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions

Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions

Background Amplivant is a molecularly optimized Toll-like receptor 2 ligand that can be covalently conjugated to tumor peptide antigens. In preclinical models, amplivant-adjuvanted synthetic long peptides (SLPs) strongly enhanced antigen presentation by dendritic cells, T cell priming and induction...

Full description

Bibliographic Details
Main Authors: Hans Gelderblom, Sjoerd H van der Burg, Ferry Ossendorp, Peggy J de Vos van Steenwijk, Mariette I E van Poelgeest, Inge Roozen, Willem-Jan Krebber, Cornelis J M Melief, Frank M Speetjens, Marij J P Welters, Nikki M Loof, Sanne Boekestijn, Catharina A H Janssen, Marije Slingerland, Gijs G Zom, A Rob P M Valentijn, Nico J Meeuwenoord, Gijs A van der Marel, Dmitri V Filippov
Format: Article
Language:English
Published: BMJ Publishing Group 2022-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/10/e005016.full

Internet

https://jitc.bmj.com/content/10/10/e005016.full

Similar Items